Can I Take Lion's Mane with MK-677 (Ibutamoren)?

What MK-677 and Lion's Mane Actually Do

MK-677 (ibutamoren) is a non-peptide ghrelin receptor agonist that stimulates growth hormone (GH) release from the anterior pituitary. Lion's mane is a culinary-medicinal mushroom studied primarily for its neurotrophic properties. The two compounds target different receptor systems and are metabolized through different enzymatic pathways.

MK-677: A Ghrelin Mimetic

MK-677 binds the growth hormone secretagogue receptor (GHS-R1a), the same receptor targeted by endogenous ghrelin. A 2-year randomized trial in healthy older adults (N=65) showed that 25 mg daily raised GH and IGF-1 to levels seen in young adults without altering cortisol or prolactin [1]. The drug is not FDA-approved for any indication and remains investigational. It is orally bioavailable with a half-life of approximately 6 hours, and GH pulsatility is maintained rather than producing the flat elevations seen with exogenous GH injections [2].

Lion's Mane: A Neurotrophic Mushroom

Hericium erinaceus contains two classes of bioactive compounds: hericenones (found in the fruiting body) and erinacines (found in the mycelium). Both stimulate nerve growth factor (NGF) synthesis in astrocytes. A double-blind, placebo-controlled trial in 30 Japanese women with mild cognitive impairment found that 3 g/day of lion's mane powder for 16 weeks significantly improved cognitive function scores compared to placebo [3]. The compound is metabolized primarily through hepatic glucuronidation, not cytochrome P450 enzymes, which reduces the likelihood of drug-drug metabolic interference [4].

Is There a Direct Drug Interaction?

No published study has tested the combination of MK-677 and lion's mane in humans or animals. No interaction alert appears in the Natural Medicines Comprehensive Database, Lexicomp, or the Mayo Clinic drug interaction checker as of May 2026. This absence of data does not confirm safety. It means the combination has simply not been studied.

Pharmacokinetic Analysis

A pharmacokinetic interaction would require both substances to compete for the same metabolic enzymes. MK-677 is metabolized primarily by CYP3A4 [2]. Lion's mane constituents are processed largely through phase II conjugation (glucuronidation), with minimal CYP3A4 involvement in vitro [4]. Based on available metabolic data, a clinically significant pharmacokinetic interaction is unlikely. Neither compound is a known strong inducer or inhibitor of the other's primary metabolic pathway.

Pharmacodynamic Overlap

The more relevant concern is pharmacodynamic. Both compounds could theoretically influence IGF-1 signaling, though through different mechanisms. MK-677 raises IGF-1 directly by increasing GH secretion. Lion's mane has shown modest effects on NGF and brain-derived neurotrophic factor (BDNF) pathways, which share downstream cross-talk with IGF-1 receptor signaling in neuronal tissue [5]. Whether this cross-talk produces any additive or antagonistic effect on systemic IGF-1 levels has not been measured.

The IGF-1 Question

MK-677 reliably raises IGF-1. In the Nass et al. Study, 25 mg daily for 12 months increased serum IGF-1 by approximately 60 ng/mL in older adults, bringing levels into the young-adult reference range [1]. This is the drug's intended pharmacologic action.

Does Lion's Mane Affect IGF-1?

No human trial has reported lion's mane raising systemic IGF-1 levels. One rodent study showed erinacine A increased hippocampal NGF without measurable changes in circulating IGF-1 [6]. The concern about additive IGF-1 elevation is theoretically grounded but has no supporting clinical data. If you are taking MK-677 and adding lion's mane, your IGF-1 levels are being driven by ibutamoren, not the mushroom.

Why IGF-1 Monitoring Matters

Chronically elevated IGF-1 above the age-adjusted reference range has been associated with increased colorectal cancer risk in observational data. The European Prospective Investigation into Cancer and Nutrition (EPIC) found that individuals in the highest quartile of circulating IGF-1 had a 1.58-fold higher risk of colorectal cancer compared to the lowest quartile (95% CI: 1.19 to 2.10) [7]. Checking IGF-1 at baseline and every 8 to 12 weeks while on MK-677 is standard practice in research protocols regardless of supplement use.

Bleeding Risk: Lion's Mane and Platelet Function

Lion's mane contains compounds that inhibit platelet aggregation in vitro. A 2016 study isolated hericenone B and demonstrated dose-dependent inhibition of collagen-induced platelet aggregation in human platelet-rich plasma [8]. The clinical significance of this finding is uncertain because in-vitro platelet inhibition does not always translate to bleeding events in humans.

Who Should Be Cautious

MK-677 itself has no documented anticoagulant or antiplatelet activity. The concern here is one-sided: lion's mane, not ibutamoren. If you take anticoagulants (warfarin, apixaban, rivaroxaban), antiplatelet agents (aspirin, clopidogrel), or have a bleeding disorder, the combination of lion's mane with those medications carries a theoretical bleed-potentiation risk. This risk exists with or without MK-677 in the picture. Report any unusual bruising, prolonged bleeding from cuts, or dark stools to your physician.

Practical Bleeding Monitoring

A baseline CBC with platelet count before starting lion's mane is reasonable. Repeat testing at 8 to 12 weeks. No standardized platelet-function assay cutoff exists for lion's mane, so clinical signs (bruising, gingival bleeding, petechiae) remain the primary monitoring tool.

MK-677 and Blood Glucose: What Lion's Mane Does Not Fix

MK-677 raises fasting blood glucose. This is a well-documented, dose-dependent effect. In the Nass et al. Trial, fasting glucose increased by approximately 0.3 mmol/L (5.4 mg/dL) on average, and HbA1c rose modestly in some participants over 12 months [1]. GH is a counter-regulatory hormone to insulin, and any effective GH secretagogue will produce some degree of insulin resistance.

Lion's Mane and Glucose: Separate Mechanisms

Some rodent studies suggest lion's mane polysaccharides may improve insulin sensitivity through alpha-glucosidase inhibition [9]. A small human study (N=20, type 2 diabetes, 12 weeks) reported modest reductions in fasting glucose with Hericium erinaceus extract, but the trial was not powered for definitive conclusions [10]. The idea that lion's mane could "offset" MK-677's glucose-raising effect is speculative. No study has tested this combination. Do not rely on a mushroom supplement to manage the metabolic effects of a GH secretagogue.

Glucose Monitoring Protocol

If you take MK-677, check fasting glucose and HbA1c at baseline, 4 weeks, and every 12 weeks thereafter. This applies whether or not you add lion's mane. Anyone with prediabetes (fasting glucose 100 to 125 mg/dL) or type 2 diabetes should discuss MK-677 with their endocrinologist before use.

Dose Separation: Is Timing Important?

There is no pharmacokinetic basis for mandatory dose separation between MK-677 and lion's mane. They do not compete for the same transporters, binding sites, or metabolic enzymes based on available data.

Why Some Practitioners Suggest Spacing

A 2- to 4-hour window between doses is sometimes recommended to reduce gastrointestinal overlap. MK-677 can increase appetite and cause transient water retention. Lion's mane at higher doses (2,000 to 3,000 mg) may cause mild GI discomfort in some users. Taking both simultaneously on an empty stomach could amplify nausea or bloating in sensitive individuals. This is a tolerability consideration, not a pharmacologic one.

A Reasonable Approach

Take MK-677 at bedtime (its most common timing in research protocols, since GH secretion peaks during sleep). Take lion's mane in the morning or with a meal. This naturally separates the two by 8 or more hours and aligns each compound with its intended use: MK-677 for overnight GH pulsatility, lion's mane for daytime cognitive support.

What to Monitor If You Take Both

A monitoring framework for the MK-677 plus lion's mane combination should cover the pharmacologic effects of each compound individually, since no interaction-specific monitoring protocol exists.

Baseline Labs (Before Starting)

• Fasting glucose and HbA1c
• IGF-1 (age-adjusted reference range)
• CBC with platelet count
• Comprehensive metabolic panel (CMP) including liver enzymes
• Body weight and waist circumference

Follow-Up Labs (8 to 12 Weeks, Then Quarterly)

• Fasting glucose and HbA1c (MK-677 effect)
• IGF-1 (MK-677 effect; target within age-adjusted range)
• CBC with platelet count (lion's mane antiplatelet concern)
• Liver enzymes (general supplement monitoring)

Clinical Signs to Report

Watch for peripheral edema (MK-677 causes water retention in approximately 10% of users [1]), joint stiffness or carpal tunnel symptoms (signs of excessive GH/IGF-1), unusual bruising or bleeding (lion's mane antiplatelet activity), and persistent GI discomfort (either compound).

What If You Are Already Taking Both?

If you have been using MK-677 and lion's mane together without adverse effects, the absence of problems is informative but not definitive. Continue your monitoring schedule. Do not increase the dose of either compound without reassessing labs. The combination has not been studied long-term (or at all, formally), so ongoing vigilance replaces the comfort that clinical trial data would otherwise provide.

When to Stop

Discontinue lion's mane and contact your physician if you experience unexplained bleeding, dark or tarry stools, or new easy bruising. Discontinue MK-677 and seek medical evaluation if fasting glucose exceeds 126 mg/dL on two separate readings, if you develop symptoms of carpal tunnel syndrome, or if IGF-1 rises above 1.5 times the upper limit of your age-adjusted reference range.

The Bottom Line on Safety

The MK-677 plus lion's mane combination carries no documented pharmacokinetic interaction. The pharmacodynamic concerns (additive IGF-1 signaling, lion's mane antiplatelet activity, MK-677 glucose elevation) are theoretical and individually manageable with routine blood work. Neither compound is FDA-approved for therapeutic use, meaning you are operating outside regulatory guardrails entirely. A prescriber familiar with GH secretagogues should supervise MK-677 use. Lion's mane is generally well-tolerated, but its antiplatelet properties deserve respect in anyone on concurrent blood thinners.

Fasting glucose at 4 weeks and IGF-1 at 12 weeks remain the two most actionable lab values for anyone on MK-677, with or without lion's mane in the regimen.